Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 36
01
Overview
A Phase 3 trial of mirikizumab in ulcerative colitis (UC), sponsored by Eli Lilly and Company. Started Jul 2018; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03519945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519945.